Option Care Health Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw all director nominees elected and key proposals, including auditor ratification and executive compensation, approved by strong majorities. 2025 financials showed solid growth despite industry challenges, with ongoing initiatives to improve patient care and address recent performance issues.
-
The session highlighted a disruptive Q1 with a $175M revenue guidance reduction, but EBITDA guidance was maintained through cost controls and operational focus. Investments in technology, commercial resources, and share repurchases are prioritized, while the business remains confident in long-term growth and portfolio diversification.
-
Q1 2026 saw revenue up just over 1% year-over-year, with strong acute growth offset by chronic portfolio headwinds and a $55M gross profit impact from CID. Full-year guidance was revised downward for revenue but maintained for EBITDA and EPS, with decisive actions underway to rebuild growth.
-
Exceeded 2025 targets and expanded patient reach, with a $25M-$35M headwind expected in 2026 due to therapy mix changes. Acute business is set for mid-single digit growth, supported by operational scale and advanced practitioner models, while capital deployment remains flexible.
-
Strong financial performance with double-digit growth, diversified revenue streams, and robust cash flow support continued investment in M&A, technology, and expansion. Positioned to benefit from industry shifts to lower-cost care, with minimal future impact from Stelara and biosimilars.
Fiscal Year 2025
-
Revenue grew 13% to $5.6B in 2025, with strong acute and chronic therapy growth and expanding payer partnerships. 2026 guidance reaffirms 4% revenue growth at midpoint, $480–505M adjusted EBITDA, and $340M+ operating cash flow, despite Stelara biosimilar headwinds.
-
The business is positioned for above-market growth through a broad national footprint, strong payer and pharma relationships, and a robust drug pipeline. Despite a $70 million EBITDA headwind from STELARA and biosimilars in 2025, guidance for sales and earnings was raised, and ongoing industry trends favor alternate care settings and cost efficiency.
-
Strong financial performance and disciplined capital management have driven growth, with a focus on chronic therapies and strategic tuck-in acquisitions. Market share gains from competitor exits and robust payer relationships support ongoing expansion, while operational shifts like the Stelara transition and increased infusion suite utilization shape future outlook.
-
The business is leveraging national scale and local execution to grow in both acute and chronic infusion therapies, despite headwinds from Stelara's pricing changes and biosimilar transitions. Financial guidance remains positive, with EBITDA and EPS growth expected, supported by strong cash flow and disciplined capital deployment.
-
Leadership emphasized strong culture and mission alignment, with robust financial performance and raised guidance for 2025. Despite STELARA-related headwinds and biosimilar impacts, growth remains on track, supported by operational initiatives, payer partnerships, and strategic capital deployment.
-
Third quarter saw 12% revenue growth, strong acute and chronic therapy performance, and raised full-year guidance. Stelara biosimilar adoption remains a headwind, but operational momentum and investments in technology and clinical models support continued growth.
-
The company remains the largest U.S. home infusion provider, leveraging scale and clinical expertise to drive high single-digit revenue and double-digit EBITDA growth. A diverse drug portfolio, disciplined capital deployment, and adaptability to market changes—including biosimilar and competitor dynamics—support continued expansion and strong cash flow generation.
-
Second quarter saw 15%+ revenue growth, strong execution in both acute and chronic therapies, and increased full-year guidance. Investments in technology, suite-based care, and advanced practitioner models are fueling growth, with robust cash flow and active capital deployment.
-
Leadership highlighted strong Q1 results and raised guidance, citing resilience and market share gains, especially in chronic therapies. Investments in people, technology, and in-house nursing drive efficiency and growth, while policy headwinds like Stelara LOE are being managed through portfolio diversity and payer negotiations.
-
Strong Q1 growth was driven by national scale, strategic acquisitions, and robust clinical capabilities. Investments in technology, infrastructure, and payer relationships support continued expansion, while a balanced portfolio and efficient operations ensure financial resilience.
-
Strong first quarter results were driven by acute and chronic therapy growth, payer partnerships, and investments in advanced care models. The platform is well positioned for biosimilar transitions and regulatory changes, with robust free cash flow supporting M&A and share repurchases.
-
First quarter revenue grew 16% year-over-year, with strong performance in both acute and chronic therapies. Adjusted EBITDA rose 13.7%, and guidance for the year was raised on the lower end, despite ongoing uncertainties around tariffs and STELARA economics.
-
A national healthcare platform reported strong financial growth, resilient performance amid industry headwinds, and continued investments in technology and clinical infrastructure. Strategic acquisitions, a focus on biosimilars, and advocacy for regulatory changes position the business for further expansion and stable profitability in 2025.
Fiscal Year 2024
-
Q4 2024 saw 19.7% revenue growth, strong cash flow, and continued margin expansion, driven by rare and orphan therapies and improved supply chain conditions. 2025 guidance reflects growth despite a $60–$70 million Stelara headwind and includes the IntraMed Plus acquisition.
-
Strong Q4 progress and robust partnerships are driving growth, with ongoing negotiations on Stelara expected to conclude by year-end. Expansion in infusion suites, new therapy areas, and payer collaborations support a positive outlook, while disciplined capital allocation and strong cash flow underpin confidence in sustained growth.
-
The company highlighted its leadership in home infusion therapy, strong financial performance, and resilient capital structure. Despite supply chain and drug pricing challenges, it expects continued growth, high patient satisfaction, and strategic capital deployment through M&A and share repurchases.
-
Strong operational performance and financial health continue, with 19 consecutive quarters of meeting commitments and a robust balance sheet. While Stelara presents near-term headwinds and a margin reset, the business remains well positioned for growth, leveraging investments and strategic partnerships.
-
Q3 saw 17% revenue growth, strong cash flow, and sequential gross profit gains, despite IV bag shortages and hurricane disruptions. Chronic therapies face 2025 gross profit headwinds from Stelara pricing changes, but medium-term growth outlook remains positive.
-
Q2 2024 saw 14.8% revenue growth, strong cash flow, and operational recovery from cyber and supply chain disruptions. Chronic therapies led growth, new rare/orphan drugs outperformed, and guidance was raised for revenue and EBITDA. Infusion suite expansion and capital deployment continued.
-
Resilient performance and strong growth continue, driven by home infusion demand, innovation in rare and chronic therapies, and strategic expansion of clinical resources. Financial outlook remains robust, with ongoing margin management and capital deployment focused on M&A and share repurchase.
-
Strong recovery from the Change Healthcare disruption is underway, with full normalization expected by year-end. Margin growth is driven by disciplined focus on gross profit dollars, strategic expansion in limited distribution drugs, and ongoing portfolio innovation. Robust cash flow and a strong balance sheet support renewed M&A activity and a positive midterm growth outlook.
-
A leading infusion services provider highlighted its national reach, operational efficiency, and strong payer relationships. Recent results showed double-digit revenue growth and improved EBITDA, with resilience demonstrated during industry disruptions.